MedPath

Tirofiban

Generic Name
Tirofiban
Brand Names
Aggrastat
Drug Type
Small Molecule
Chemical Formula
C22H36N2O5S
CAS Number
144494-65-5
Unique Ingredient Identifier
GGX234SI5H
Background

Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.

Indication

For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.

Associated Conditions
Cardiovascular Events

Tirofiban for Patients Treated With Alteplase

Phase 2
Terminated
Conditions
Ischemic Stroke
Interventions
First Posted Date
2017-11-29
Last Posted Date
2020-09-09
Lead Sponsor
Capital Medical University
Target Recruit Count
30
Registration Number
NCT03357133
Locations
🇨🇳

The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China

🇨🇳

Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Luzhou People's Hospital, Luzhou, Sichuan, China

and more 4 locations

Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients

Phase 4
Completed
Conditions
Non-ST Elevation Myocardial Infarction
Interventions
First Posted Date
2017-04-14
Last Posted Date
2018-07-17
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
140
Registration Number
NCT03114995

Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients

Phase 1
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2017-03-13
Last Posted Date
2017-03-13
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
90
Registration Number
NCT03078257
Locations
🇨🇳

First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Terminated
Conditions
Non-ST Elevation Myocardial Infarction (NSTEMI)
Interventions
First Posted Date
2017-02-09
Last Posted Date
2023-12-11
Lead Sponsor
Inova Health Care Services
Target Recruit Count
10
Registration Number
NCT03048019
Locations
🇺🇸

Inova Health Care System, Falls Church, Virginia, United States

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Phase 4
Completed
Conditions
STEMI - ST Elevation Myocardial Infarction
Coronary Artery Disease
Interventions
First Posted Date
2016-11-30
Last Posted Date
2020-02-21
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
122
Registration Number
NCT02978040
Locations
🇨🇭

Bern University Hospital, Bern, Switzerland

🇮🇹

University of Ferrara, Ferrara, Italy

🇮🇹

University of Naples Federico II, Naples, Italy

Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease

Phase 4
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2014-11-19
Last Posted Date
2014-12-02
Lead Sponsor
Second Hospital of Jilin University
Target Recruit Count
1000
Registration Number
NCT02294994
Locations
🇨🇳

The sencond hospital of Jilin University, Changchun, Jilin, China

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

Phase 4
Completed
Conditions
Myocardial Infarction
Percutaneous Coronary Intervention
Thrombolytic Therapy
Interventions
First Posted Date
2014-05-06
Last Posted Date
2018-08-07
Lead Sponsor
Fudan University
Target Recruit Count
362
Registration Number
NCT02131220
Locations
🇨🇳

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Intracoronary Tirofiban on No-Reflow Phenomena

Phase 4
Completed
Conditions
No-Reflow Phenomenon
Interventions
Other: Placebo
First Posted Date
2014-02-04
Last Posted Date
2014-02-04
Lead Sponsor
TC Erciyes University
Target Recruit Count
162
Registration Number
NCT02054000
Locations
🇹🇷

Erciyes University School of Medicine, Kayseri, Turkey

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

Phase 1
Completed
Conditions
Renal Insufficiency
Interventions
First Posted Date
2013-01-11
Last Posted Date
2014-03-27
Lead Sponsor
Medicure
Target Recruit Count
25
Registration Number
NCT01766154
Locations
🇺🇸

Avail Clinical Research, LLC, DeLand, Florida, United States

Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

Phase 3
Conditions
Non-ST Segment Elevation Acute Coronary Syndrome
Interventions
First Posted Date
2012-08-08
Last Posted Date
2012-12-18
Lead Sponsor
Pusan National University Yangsan Hospital
Target Recruit Count
100
Registration Number
NCT01660373
Locations
🇰🇷

Pusan National University Yangsan Hospital, Yangsan, Kyeongsangnamdo, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath